BTTX Key Statistics, Chart & Performance
The current stock price of BTTX is 0.0446 USD. In the past month the price decreased by -78.14%. In the past year, price decreased by -95.79%.
BTTX Latest News, Press Relases and Analysis
BTTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 31.27 | 39.67B | ||
| DOCS | DOXIMITY INC-CLASS A | 31.38 | 9.64B | ||
| WAY | WAYSTAR HOLDING CORP | 27.61 | 7.06B | ||
| HTFL | HEARTFLOW INC | N/A | 2.68B | ||
| CERT | CERTARA INC | 18.17 | 1.45B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.34B | ||
| SDGR | SCHRODINGER INC | N/A | 1.28B | ||
| PHR | PHREESIA INC | N/A | 1.22B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.10B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 636.25 | 1.08B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8.11 | 963.98M | ||
| CTEV | CLARITEV CORP | N/A | 898.41M |
Related stock screener links
About BTTX
Company Profile
Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The firm's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
Company Info
BETTER THERAPEUTICS INC
548 Market St. #49404
San Francisco CALIFORNIA US
CEO: Suying Liu
Employees: 54
Phone: 14158872311
BETTER THERAPEUTICS INC / BTTX FAQ
What does BTTX do?
Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California and currently employs 54 full-time employees. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The firm's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
What is the current price of BTTX stock?
The current stock price of BTTX is 0.0446 USD. The price increased by 27.43% in the last trading session.
What is the dividend status of BETTER THERAPEUTICS INC?
BTTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BTTX stock?
BTTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does BETTER THERAPEUTICS INC have?
BETTER THERAPEUTICS INC (BTTX) currently has 54 employees.
Can you provide the market cap for BETTER THERAPEUTICS INC?
BETTER THERAPEUTICS INC (BTTX) has a market capitalization of 2.22M USD. This makes BTTX a Nano Cap stock.
Can you provide the upcoming earnings date for BETTER THERAPEUTICS INC?
BETTER THERAPEUTICS INC (BTTX) will report earnings on 2024-03-27, after the market close.
BTTX Technical Analysis
BTTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BTTX. BTTX has a bad profitability rating. Also its financial health evaluation is rather negative.
BTTX Financial Highlights
Over the last trailing twelve months BTTX reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 43.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -294.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BTTX Forecast & Estimates
8 analysts have analysed BTTX and the average price target is 5.36 USD. This implies a price increase of 11906.73% is expected in the next year compared to the current price of 0.0446.
For the next year, analysts expect an EPS growth of 50.82% and a revenue growth -100% for BTTX